ArticleTherapeutic advances in hematology2025
The efficacy and safety of asciminib treatment in patients with chronic myeloid leukemia as a second-line or beyond second-line treatment: a systematic review and meta-analysis.
Zixin Fan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.